Peripheral artery disease: CKD tied to excess risk for CV events

  • Hopley CW & al.
  • Vasc Med
  • 24 Jul 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Comorbid chronic kidney disease (CKD) is associated with excess risk for cardiovascular (CV) ischemic events and all-cause mortality in patients with peripheral arterial disease (PAD).

Why this matters

  • Risk increases with degree of renal impairment.

Study design

  • Post hoc analysis of the EUCLID randomized trial involving 13,483 patients with PAD receiving ticagrelor (Brilinta) or clopidogrel (Plavix).
  • 3332 (24.7%) had comorbid CKD (stage 4/5, n=237).
  • Primary composite endpoint: CV death, myocardial infarction (MI), or ischemic stroke.
  • Median follow-up, ~30 months.
  • Funding: AstraZeneca.

Key results

  • CKD was associated with a higher rate of the primary endpoint vs no CKD (6.75 vs 3.72 events/100 patient-years), corresponding to a 45% increased risk (adjusted [a]HR, 1.45; P<.0001 style="list-style-type:circle;">
  • Risk rose 20% with each 10 mL/minute/1.73 m2 decrease in estimated glomerular filtration rate below 70 mL/minute/1.73 m2 (HR, 1.20; P<.0001>
  • The effect appeared driven by CV death (aHR, 1.42; P=.0001) and MI (aHR, 1.55; P<.0001 rather than ischemic stroke>
  • All-cause mortality also increased (aHR, 1.40; P<.0001>
  • CKD was associated with a 51% elevated risk for minor bleeding (aHR, 1.51; P=.0205), but not major bleeding (P=.2220).
  • No association observed with hospitalization for acute limb ischemia (P=.8074), major amputation (P=.6371), or their composite (P=.9082).
  • Limitations

    • Few major bleeding events.